Click on the session name for more details about the session
| Time | Program |
| 02:00 PM - 04:00 PM |
Pre-Conference | Workshop by BiologixFerriprox® in the Management of Iron Overload
Pre-Conference | Workshop by BiologixThursday, March 24, 2022 at 02:00 PM - 04:00 PM Details : Ferriprox® in the Management of Iron OverloadChairperson : Fatheya Al KhajaUnited Arab EmiratesTopics : UK experience in Beta Thalassemia Iron Overload Management
Paul TelferUnited Kingdom02:00 PM - 02:40 PM
UAE experience in the management of severe iron overload (DFP monotherapy vs Combination) & Discussion
Hani DwedarUnited Arab Emirates02:40 PM - 03:00 PM
Adult Case Presentation & Discussion
 Hazzaa Al ZahraniSaudi Arabia03:00 PM - 03:20 PM
Pediatric Case Presentation & Discussion
Yasser WaliOman03:20 PM - 03:40 PM
Adult Case Presentation & Discussion
Amar LalUnited Arab Emirates03:40 PM - 04:00 PM
|
| 04:00 PM - 04:25 PM | Industry Symposium by Novo NordiskN8-GP (turoctocog alfa pegol; Esperoct): An extended half-life recombinant factor VIII molecule for patients with haemophilia A |
| 04:30 PM - 04:55 PM | Industry Symposium by MSDAntifungal prophylaxis in high-risk patients with hematological malignancies |
| 05:00 PM - 05:25 PM | Industry Symposium by RocheDLBCL: Where do we stand in 2022? |
| 05:30 PM - 06:25 PM |
Industry Symposium by NovartisASH Updates in SCD & Cardiovascular Risk in PV
Industry Symposium by NovartisThursday, March 24, 2022 at 05:30 PM - 06:25 PM Chairperson : Mahmoud MarashiUnited Arab EmiratesTopics : ASH Updates in SCD
Deepa ManwaniUnited Arab Emirates05:30 PM - 05:55 PM
Cardiovascular Risk in PV
Hadeel AmmarUnited Arab Emirates06:00 PM - 06:25 PM
|
| 06:30 PM - 06:55 PM | Industry Symposium by BMS 1Management of transfusion-dependent thalassemia: Unmet needs and novel therapies |
| 07:00 PM - 07:25 PM | Industry Symposium by SandozBiosimilars for treating lymphoma : Rixathon “Rituximab Biosimilar by Sandoz” |
| 07:30 PM - 07:55 PM |
Industry Symposium by SanofiThe Era of MRD Negativity and it’s impact on MM Management & Isatuximab phase 3 pivotal clinical Trial IKEMA trial
Industry Symposium by SanofiThursday, March 24, 2022 at 07:30 PM - 07:55 PM Topics : The Era of MRD Negativity and it’s impact on MM Management
Arif AlamUnited Arab Emirates07:30 PM - 07:40 PM
Isatuximab phase 3 pivotal clinical Trial IKEMA trial
Arif AlamUnited Arab Emirates07:40 PM - 07:55 PM
|
| 08:00 PM - 08:25 PM | Industry Symposium by AstraZenecaHow to Select BTKI for your Patient?... The luxury to choose |
| 08:30 PM - 08:55 PM | Industry Symposium by BMS 2TDT.. What has changed? |
| Time | Program |
| 02:00 PM - 02:25 PM | Industry Symposium by Eli LillyIndolent lymphoproliferative disease |
| 02:30 PM - 02:55 PM | Industry Symposium by AstellasADMIRAL Study: The paradigm shift for R/R FLT3 mutated AML Patients |
| 02:55 PM - 03:00 PM | Opening Remarks |
| 03:00 PM - 04:20 PM |
Session 1: Myeloid Disorders
Session 1: Myeloid DisordersFriday, March 25, 2022 at 03:00 PM - 04:20 PM Chairperson : Salam Al KindiOmanMahmoud MarashiUnited Arab EmiratesMurtadha AlkhaboriOmanTopics : Management of PV in 2022
Ayalew TefferiUnited States03:00 PM - 03:20 PM
Diagnosis and Prognosis of AML in 2022
Michael SavonaUnited States03:20 PM - 03:40 PM
Diagnosis, Prognosis and management of MDS including MDS-MPN
Ayalew TefferiUnited States03:40 PM - 04:00 PM
Treatment of AML in 2022, moving forward from 7+3
Michael SavonaUnited States04:00 PM - 04:20 PM
|
| 04:25 PM - 04:40 PM | ALL Case Presentations |
| 04:45 PM - 05:25 PM |
Q&A - Meet the Experts (Day 1)
Q&A - Meet the Experts (Day 1)Friday, March 25, 2022 at 04:45 PM - 05:25 PM Chairperson : Salam Al KindiOmanMurtadha AlkhaboriOmanMahmoud MarashiUnited Arab EmiratesTopics : Q&A - Meet the Experts
Ayalew TefferiUnited States07:10 PM - 07:50 PM
Q&A - Meet the Experts
Michael SavonaUnited States07:10 PM - 07:50 PM
Q&A - Meet the Experts
Amar LalUnited Arab Emirates04:45 PM - 05:25 PM
|
| 05:30 PM - 05:55 PM | Industry Symposium by StemlineBlastic Plasmacytoid Dendritic Cell Neoplasm BPDCN (Disease state, History, Diagnosis and Novel therapies) |
| 05:55 PM - 06:20 PM | Industry Symposium by Abbvie BCL2i outcomes in high-risk CLL patients |
| Time | Program |
| 01:30 PM - 01:55 PM | Industry Symposium by MSD 2The management paradigm of cHL |
| 02:00 PM - 02:25 PM | Industry Symposium by Amgen Key Highlights in Managing RRMM |
| 02:30 PM - 02:55 PM | Industry Symposium by KyowaKirinCutaneous T-Cell Lymphomas : Overview and clinical considerations |
| 03:00 PM - 03:45 PM | Session 2: Best of ASH |
| 03:50 PM - 05:10 PM |
Session 3: Lymphoproliferative disorders I
Session 3: Lymphoproliferative disorders ISaturday, March 26, 2022 at 03:50 PM - 05:10 PM Chairperson : Arif AlamUnited Arab EmiratesShahrukh HashmiUnited Arab EmiratesFaraz KhanUnited Arab EmiratesTopics : How I treat Indolent lymphoma in 2022
Jeremy AbramsonUnited States03:50 PM - 04:10 PM
Treatment of Aggressive B cell lymphoma in 2022
Jeremy AbramsonUnited States04:10 PM - 04:30 PM
CAR T cells in lymphoma and ALL
Jeremy AbramsonUnited States04:30 PM - 04:50 PM
How I treat CNS lymphoma in 2022
Grzegorz NowakowskiUnited States04:50 PM - 05:10 PM
|
| 05:15 PM - 06:35 PM |
Session 4: Lymphoproliferative disorders II Session 4: Lymphoproliferative disorders II
Chairperson : Hassan Al YaseenUnited Arab EmiratesKayane MheidlyUnited Arab EmiratesTopics : How I treat relapsed Hodgkin lymphoma
Grzegorz NowakowskiUnited States05:15 PM - 05:35 PM
Treatment of relapsed Follicular lymphoma in 2022
Grzegorz NowakowskiUnited States05:35 PM - 05:55 PM
Diagnosis and choice of CLL therapy in 2022, How do you select?
Sameer ParikhUnited States05:55 PM - 06:15 PM
Complications of CLL and CLL therapy
Sameer ParikhUnited States06:15 PM - 06:35 PM
|
| 06:40 PM - 06:50 PM | Challenging Case Presentation |
| 06:50 PM - 07:10 PM |
Lymphoma Case Presentations
Lymphoma Case PresentationsSaturday, March 26, 2022 at 06:50 PM - 07:10 PM Topics : Case Presentation 1
Amar LalUnited Arab Emirates06:50 PM - 06:55 PM
Case Presentation
Faraz KhanUnited Arab Emirates06:55 PM - 07:00 PM
Case Presentation 2
Amar LalUnited Arab Emirates07:00 PM - 07:05 PM
Case Presentation
Arif AlamUnited Arab Emirates07:05 PM - 07:10 PM
|
| 07:10 PM - 07:50 PM |
Q&A - Meet the Experts (Day 2)
Q&A - Meet the Experts (Day 2)Saturday, March 26, 2022 at 07:10 PM - 07:50 PM Chairperson : Kayane MheidlyUnited Arab EmiratesHassan Al YaseenUnited Arab EmiratesArif AlamUnited Arab EmiratesAmar LalUnited Arab EmiratesShahrukh HashmiUnited Arab EmiratesFaraz KhanUnited Arab EmiratesTopics : Q&A - Meet the Experts
Ranjana AdvaniUnited States06:15 PM - 06:55 PM
Q&A - Meet the Experts
Jeremy AbramsonUnited States06:15 PM - 06:55 PM
Q&A - Meet the Experts
Grzegorz NowakowskiUnited States06:35 PM - 07:15 PM
Q&A - Meet the Experts
Sameer ParikhUnited States06:35 PM - 07:15 PM
|
| 07:55 PM - 08:20 PM | Industry Symposium by Janssen 1New Horizons in CLL management |
| 08:20 PM - 08:45 PM | Industry Symposium by Takeda 1Acquired Hemophilia: The Tawam Experience |
| 08:45 PM - 09:10 PM | Industry Symposium by Takeda 2Maximizing patients outcome in Gaucher Disease |
| Time | Program |
| 02:00 PM - 02:25 PM | Industry Symposium by Janssen 2Advances in Management of Newly Diagnosed Multiple Myeloma |
| 02:30 PM - 02:55 PM |
Industry Symposium by AstraZeneca 2Beyond COVID 19 Vaccination: Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19
Industry Symposium by AstraZeneca 2Sunday, March 27, 2022 at 02:30 PM - 02:55 PM Chairperson : Mahmoud MarashiUnited Arab EmiratesTopics : Beyond COVID 19 Vaccination: Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19
Mustaqeem SiddiquiUnited Arab Emirates02:20 PM - 02:55 PM
|
| 03:00 PM - 04:20 PM |
Session 5: Plasma Cell Disorders
Session 5: Plasma Cell DisordersSunday, March 27, 2022 at 03:00 PM - 04:20 PM Chairperson : Ahmad AlhuraijiKuwaitMustaqeem SiddiquiUnited Arab EmiratesTopics : What are the important investigations in the new cases of myeloma and how do you follow up the case including MRD
Jesus San-MiguelSpain03:00 PM - 03:20 PM
Is there still a role for ASCT in 2022
Morie GertzUnited States03:20 PM - 03:40 PM
Can myeloma be cured in the era of new therapies?
Jesus San-MiguelSpain03:40 PM - 04:00 PM
How I diagnose and treat amyloidosis in 2022
Morie GertzUnited States04:00 PM - 04:20 PM
|
| 04:25 PM - 05:25 PM |
Session 6: Bleeding Disorders
Session 6: Bleeding DisordersSunday, March 27, 2022 at 04:25 PM - 05:25 PM Chairperson : Amna Al MehairiUnited Arab EmiratesHadeel AmmarUnited Arab EmiratesTopics : VWD, approach to diagnosis and management
Alice MaUnited States04:25 PM - 04:45 PM
Investigation of patients with bleeding
Alice MaUnited States04:45 PM - 05:05 PM
Antiphospholipid syndrome, diagnosis and management
Alice MaUnited States05:05 PM - 05:25 PM
|
| 05:30 PM - 05:40 PM | Myeloma Case Presentations |
| 05:40 PM - 06:20 PM |
Q&A - Meet the Experts (Day 3)
Q&A - Meet the Experts (Day 3)Sunday, March 27, 2022 at 05:40 PM - 06:20 PM Chairperson : Amna Al MehairiUnited Arab EmiratesAhmad AlhuraijiKuwaitMustaqeem SiddiquiUnited Arab EmiratesHadeel AmmarUnited Arab EmiratesTopics : Q&A - Meet the Experts
Morie GertzUnited States05:25 PM - 06:05 PM
Q&A - Meet the Experts
Jesus San-MiguelSpain05:25 PM - 06:05 PM
Q&A - Meet the Experts
Alice MaUnited States05:25 PM - 06:05 PM
Q&A - Meet the Experts
Amar LalUnited Arab Emirates05:40 PM - 06:20 PM
|
Contact Us
Quick Links
Copyright All Rights Reserved © 2022 | Powered by Meeting Minds Experts.